• (PLX AI) – Roche half year revenue CHF 30,700 million vs. estimate CHF 31,400 million
  • • half year core EBIT CHF 11,652 million vs. estimate CHF 11,500 million
  • • half year core EPS CHF 10.56 vs. estimate CHF 10.12
  • • half year net income CHF 8,216 million
  • • Roche outlook for 2021 confirmed
  • • Despite the continued strong impact of biosimilars, sales are expected to grow in the low- to mid-single digit range, at constant exchange rates
  • • Core earnings per share are targeted to grow broadly in line with sales, at constant exchange rates
  • • Roche expects to increase its dividend in Swiss francs further
  • • Sales in the Pharmaceuticals Division were CHF 22 billion, a decrease of 3%
  • • Says while sales in the first quarter were still strongly affected by COVID-19 (-9%), the second quarter showed signs of recovery in some regions (+4%)

Quelle: PLX AI